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We cro砕 .sect間同lystudied the incidence and impact on quality of life of ejaculatory disorders 
caused by alpha-l adrenoceptor antagonists (tamsulosin or naftopidil) in patients with benign prostatic 
hyperplasia (BPH). By questionnaire， we queried 88 clinical BPH patients concerning ejaculatory 
disorders， who were treated with tamsulosin or naftopidil between February 1999 and August 2003. 
We investigated the difference in the incidence and types of disorders between the two drugs. Of the 
88 patients， 63 (7l.6 %) had sexual activities during the treatment. The incidence of ejaculatory 
disorders was significantly higher in the tamsulosin group (30.0 %) than in the naftopidil group (3.0 %). 
Eighty percent of patients having the disorders noticed the absence or reduced volume of semen 
although they experienced orgasms. The median quality of life index concerning the disorder was 
rated as 4， "mostly dissatisfied." 
Our results indicated that ejaculatory disorders occurred more frequently in the tamsulosin group. 
We should inform patients about this adverse effect caused by alpha-l adrenoceptor antagonists prior to 
treatment. 
(Hinyokika Kiyo 51 : 763一766，2005) 














































































Table 1. Characteristics of patients treated with tamsulosin or naftopidil 
塩酸タムスロシン群 ナフトピジル群 p値
患者数 40 48 
年齢(歳) 63.6:!: 4目3 61. 7:!: 5. I p=O.06 
投与期間(月) 17 土24 15 :! 13 p=0.09 
前立腺重量 (ml) 37. s:!: 13. 3 (n=26) 28.8:!: 8.5 (n=27) p<O.OI* 
投与前 最大尿流率 (ml!s) 13.3土 5.4(n=33) 12. I土 4.3(n=39) p=0.36 
残尿 (ml) 61 土54 (n=33) 34 土37 (11=39) p<0.05* 
排尿量 (ml) 231土140 (n=33) 205土73 (n=39) p=O目92
I-PSS 15.0:!: 6.6 (n=21) 18.3土 8.4(n=24) p=0.16 
QOL index 4.1土1.I (n=21) 4.4土 0.9(n=24) p=0.44 
投与後 最大尿流率 (ml!s) 14.6土 9.0(n=l7) 14.9:!: 6.0 (11=25) p=0.49 
残尿 (ml) 44-土54 (n=17) 33 :!:38 (n=25) p=O.57 
排尿量(ml) 245 :!:157 (n=l7) 273 :! 193 (11=25) p=0.89 
I-PSS 10.8土 6.4.(n=11) 11. 8土 5.9(n=24) p=0.49 
QOL index 2.6:!: 1.7 (n=11) 3.3:!: 1.3 (n=24) p=0.36 
*: statistically significant， Mann-Whitney U test 
765 射精障害古屋，ほか :αlブロッカー
















* p<O. 001， Fischer's exact test 
Characteristics of patients having ejaculatory disorders caused by tamsulosin or naftopidil 
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